Beta Bionics (NASDAQ:BBNX) Stock Falls 5.2% – Should You Sell?

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) fell 5.2% on Tuesday. The company traded as low as $19.41 and last traded at $19.4550. 188,470 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 1,187,184 shares. The stock had previously closed at $20.52.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics’ integration of the Eversense 365 continuous glucose monitor with its iLet automated insulin-delivery ecosystem could expand CGM choice and strengthen the company’s diabetes-management platform. Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
• Neutral Sentiment: Beta Bionics said it will release third-quarter 2026 financial results after the market closes on October 27, giving investors a near-term catalyst for updates on sales, product adoption, regulatory matters and cash usage. Beta Bionics to Announce Third Quarter 2026 Financial Results
• Negative Sentiment: Multiple investor-rights firms are soliciting shareholders for a securities-fraud class action covering purchases from July 30, 2025, through February 24, 2026. The lawsuit reportedly alleges that Beta Bionics and certain executives failed to disclose or properly investigate more than 18,000 iLet-related customer complaints and issues cited in a June 2025 FDA Form 483. These are allegations, not established findings. Investors have until November 3, 2026, to seek appointment as lead plaintiff. Beta Bionics Shareholder Alert and Lead Plaintiff Deadline

Analysts Set New Price Targets

A number of analysts have commented on BBNX shares. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Wall Street Zen raised Beta Bionics from a “sell” rating to a “hold” rating in a research note on Saturday, September 19th. The Goldman Sachs Group raised their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Bank of America raised their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. Finally, Leerink Partners lifted their target price on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.91.

Beta Bionics Stock Performance

The company’s 50-day simple moving average is $18.31 and its 200 day simple moving average is $14.63. The company has a market cap of $853.91 million, a PE ratio of -11.50 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The company had revenue of $32.01 million for the quarter. Analysts forecast that Beta Bionics, Inc. will post -2.04 EPS for the current year.

Insider Activity at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the sale, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. This represents a 4.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 4,375 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $83,606.25. Following the completion of the sale, the insider owned 180,040 shares in the company, valued at $3,440,564.40. The trade was a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 97,327 shares of company stock worth $1,900,019 over the last ninety days. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Beta Bionics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Eventide Asset Management LLC boosted its position in shares of Beta Bionics by 0.8% during the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after acquiring an additional 37,476 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Beta Bionics during the 2nd quarter worth about $52,340,000. Eversept Partners LP lifted its stake in Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Beta Bionics during the fourth quarter worth approximately $40,437,000. Finally, Perceptive Advisors LLC lifted its stake in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares during the last quarter.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.